NCT06239220 2026-02-27
PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC
Dana-Farber Cancer Institute
Phase 2 Recruiting
Clinical Trials
3 trialsNCT04150562 2022-05-17
Avelumab (Bavencio) With IL-15 in Subjects With Clear-Cell Renal Carcinoma
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT02395822 2018-02-20
MT2014-25: Haplo NK With SQ IL-15 in Adult Relapsed or Refractory AML Patients
Masonic Cancer Center, University of Minnesota
Phase 2 Completed